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Background: Breast cancer is the second leading cancer worldwide. In Tanzania, though it ranks as the second
leading cancer in women after cervical cancer, hormonal receptor status is not carried out routinely in patients.
Adjuvant hormonal therapy is given without prior knowledge of hormonal receptors status and patients can incur
unnecessary costs and side effects. This study was performed to investigate the expression of hormonal receptors,
epidermal growth factor receptors (HER-2) and proliferation index of the breast cancer by Ki-67 in a few selected
patients with breast cancer at referral hospital in North-Western Tanzania. The study classified breast cancer
subtypes based on hormonal receptors status and the expression of epidermal growth factor receptors.
Results: A total of 52 cases of breast cancer were investigated. Patients’ mean age at diagnosis was 49 years. The
majority of the tumors was invasive ductal carcinoma 47 (90.4%) and 40 (76.9%) were of histological grade III.
Thirty-eight (73.1%) of the patient had lymph node metastasis at the time of diagnosis and 36 (69.2%) were at
clinical stage III. Only 3 (5.8%) patients were in clinical stage I. There was a tendency of a low level of expression of
the receptors, whereby Estrogen Receptor (ER) positive tumors were 17 (32.7%), progesterone receptor (PR) positive
tumors were 22 (42.3%), and HER-2 positive tumors were 12 (23.1%). Triple negative tumors constituted 20 (38.4%)
of the patients. Most of the tumors (75%) showed high proliferation by Ki-67. Lymph node metastasis was more
common in Triple Negative and HER enriched tumors.
Conclusion: This study showed a tendency for a low level of expression of hormonal receptors. There was a
significant proportion of Triple Negative breast cancers. Routine testing for hormonal receptors in breast cancer is
recommended before the initiation of adjuvant hormonal therapy.
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Testing for Estrogen (ER) and Progesterone (PR) receptors
expression for breast cancer patients are routinely done in
many parts of the world, as determination of estrogen and
progesterone receptors expression determines the patients
who will benefit from adjuvant hormonal therapy. In
addition, testing of HER-2 is performed to select patients
who will benefit from Trastuzumab therapy. The use of all
the three markers allows the classification of patients with
breast cancer in different categories with different tumor
types, treatment and prognosis [1,2].* Correspondence: prambau@bugando.ac.tz
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unless otherwise stated.Several studies have shown that the benefit from hor-
monal therapy is proportional to the hormonal receptors
levels [3]. HER-2 is an oncogene which belong to a
family of epidermal growth factors and is amplified in
14-25% of cases of breast cancers [4-6]. Amplification
for this gene leads to the expression of a trans-membrane
protein which can be detected by immunohistochemistry.
The current management of the breast cancer involves the
use of Trastuzumab for patients’ with amplification of this
gene [5]. In poor resource settings, these markers are not
routinely tested and it is therefore impossible to select the
patients who will benefit from adjuvant therapy. Currently
there is a need to introduce routine testing of these
markers in a poor resource settings as a mode of thera-
peutic selection in patients with breast cancer, and thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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regions of Africa [7,8]. In Tanzania, one study evaluated
60 cases of breast cancer for PR and ER status, where the
trend was poor expression of these markers with only
26.7% the patients were expected to benefit from hormo-
nal therapy. The patients were of young age with an
advanced stage at the time of presentation [8]. The same
trend was observed in Kenya where the patients had an
advanced stage of the disease with a low percentage likely
to be hormonal sensitive in all stages of the disease [9]. In
those studies HER-2 was not tested. However, one study
showed a high level of HER-2 over-expression (20.26%)
and was common in Grade III invasive ductal cancers [7].
Other studies have shown a higher rate of HER-2 gene
amplification in ductal cancers compared to lobular can-
cers; those tumors had a high histological grade with
negative ER and PR status [6,10].
With regard to age, studies have shown the trend of
negative receptor status at a young age. Women over
40 years are more likely to benefit from adjuvant endo-
crine therapy with low recurrence, whereas younger
women have a high prevalence of HER-2 over expression
and a low 5-years survival rate [11]. The expression of
ER, PR and HER-2 is used to describe breast cancer
groups which need different modalities for systemic
treatment and it can predict the prognosis of the pa-
tients. Tumors which do not express PR, ER nor HER-2
are called triple-negative tumors (TN), whereby such pa-
tients do not benefit from adjuvant therapy and are left
with the only option of chemotherapy and radiotherapy
[5,12]. Triple negative cancers account for 10-17% of all
breast cancers [5,13,14]. One study found a prevalence
of 29.3% TN tumors in African American women and
of 13.0% in non-African American women [15]. TN
breast cancers appear common in pre-menopausal
young African American women [12,15] who tend to
have an aggressive form of disease presenting as a large
tumor of grade III with pushing margins. The tumors
tend to recur and generally they tend to have a poor
outcome and a low overall survival compared to other
tumors. The metastatic patterns of these tumors tend to
be through blood and commonly involve lungs, brain
and meninges [5,12-14]. This study presents a prelimin-
ary analysis of 52 cases of breast cancer for these
markers in North-Western Tanzania. These markers
have not been studied yet in this particular setting,
where these tests are not routinely done.
Methods
This was a retrospective study done at the Bugando
Medical Centre (BMC). BMC is a consultant and teach-
ing hospital serving a population of 13 million people in
North-Western Tanzania, where all diagnoses of breast
cancer are made. Fifty-two formalin-fixed and paraffin-embedded tissue blocks were randomly selected from
archival materials at the department of pathology. Previ-
ous histology reports and patients’ files from the hospital
records were used to obtain demographic data and clin-
ical information. Histology slides were re-evaluated for
histological type and the histological grade was estab-
lished by the Modified Bloom-Richardson score system
which scores for tubular formation, nuclear pleomorph-
ism and mitotic rates within tumor cells. The clinical
stage of the disease was determined by using TNM
(AJCC cancer staging manual). This is a staging system
which measures the anatomical extent of disease based
on the extent of a primary tumor (T), the absence or
presence of and the extent of regional lymph node me-
tastasis (N) and the absence or presence of distant me-
tastasis. Hormone receptors status, Estrogen Receptor,
Progesterone Receptor and Ki-67 were determined by
ImmunoHistoChemistry (IHC) using Dako Antibodies
and Dako Autostainer (Dako, CA) at the laboratory of
the Scientific Institute of Romagna for the study and
treatment of Tumors (IRST) in Italy.
Immunohistochemistry
Four-micrometre sections of the tissue samples were
mounted on positive-charged slides (BioOptica, Milan,
Italy). Deparaffinization was carried out by xylene and
sections were rehydrated, followed by endogenous per-
oxidase activity block by 3% hydrogen peroxide solution.
Antigens unmasking was performed by using citrate buf-
fer pH 6 for 40 minutes at 98.5°C.
Mouse monoclonal anti-human antibodies for Estrogen
receptor ER (clone-NCL-L ER-6 F11) and Progesterone re-
ceptor PR (clone NCL-L-PGR) from Novocastra, Newcastle
upon Tyne, England were used at the dilution of 1:80, 1: 40
respectively. For Ki-67 and HER-2, a Mouse monoclonal
anti-human antibodies (Dako, Carpinteria, California, USA
clone MM1) at dilutions of 1:100 was used. Antibodies
were incubated on the sections for 60 minutes at room
temperature. The sections were then washed with
Phosphate Buffered Saline (PBS) and incubated with a
universal biotinylated secondary antibody and later on
rinsed in PBS. This was followed by incubation with
streptavidin-peroxidase conjugate (LSAB + Kit; DAKO
Corporation, Carpinteria, CA, USA) for 15 minutes.
Sections were rinsed again in PBS and antibody binding
was detected by staining with diaminobenzidine/hydro-
gen peroxidase chromogen solution (DAB + liquid sub-
strate–chromogen solution; DAKO Corporation). Finally,
the sections were rinsed in deionized water, counter-
stained by Mayer’s Hematoxylin, and mounted by Eukitt
(Bio-Optica).
The samples reactivity was evaluated by light micros-
copy (× 200) by two independent observers. The markers
positivity was evaluated in a semi-quantitative way. For ER
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staining was scored as 0 (Negative for receptor), nuclear
staining of less than 10%, as +1(borderline), staining be-
tween 10-75% as +2 and +3 when the staining was more
than 75%. In this study, the presence of nuclear staining
of 10% and above +2 and +3 was sufficient to classify
the cases as positive. For Ki-67, the number of stained
cells against the counted tumor cells was expressed as
a percentage and the staining of 10% or more of tumor
cells was sufficient criteria to classify the cases as positive.
Staining for HER-2 was considered as score 0 or nega-
tive when no staining was observed or when membrane
staining was less than 10% of the tumour cells. A score
of +1 was also considered negative, when showing a
faint membrane staining in less than 10% of the tumor
cells. A score +2 was considered as a weak positive
when showing a weak to moderate complete membrane
staining in more than 10% of the tumor cells. This was
also considered as negative. A score +3 was considered
as positive when there was a strong complete mem-
brane staining in more than 10% of the tumour cells
[16,17]. Staining for ER, PR, HER-2 and Ki-67 are shown in
Figure 1. The tumours were classified into four biological
subtypes: luminal A (ER + and/or PR+, HER2-), luminal BA
C
Figure 1 Immunuhistochemical staining pattern. A: Nuclear staining for E
staining for Ki-67.(ER + and/or PR+, HER2+), HER2-enriched (HER2+,
ER-, PR-) and TN (negative for all three markers) [18].
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Consent
This research is a retrospective study where histological
slides, tissue blocks and patient’s files have been used to
gather the information. The confidentiality of the patient
was maintained at all time of the study. Only histology
numbers and file numbers were used.
Limitations
Being a retrospective study, patients were not followed
up as they were referred to a cancer institute located far
away from the study area for further treatment. Tissue
blocks for immuno-stains were difficulty analyze due to
poor storage, leading to evaluation of only 52 blocks
from a total of 80 blocks selected. Statistical tests could
not be validated due to limited number of cases.B
D
R, B: Nuclear stain for PR, C: Membrane stain for HER-2 and D: Nuclear
Table 1 Clinico-pathological features of Triple Negative
cancers and non-Triple negative cancers
TN cancers Non TN
cancers
N n (%) n (%) p-value
Variable
Age (years)
Less or equal to 46 24 8 (33.3) 16 (66.6)
Above 46 28 12 (42.8) 16 (57.2) 0.339
Tumour size
Below 6 cm 26 7 (26.9) 19 (73)
Above 6 cm 26 13 (50) 13 (50) 0.077
Histological grade
Grade I 3 0 (0) 3 (100)
Grade II 9 3 (33.3) 6 (66.6)
Grade III 40 17 (42.5) 23 (57.5) 0.325
Lymph node metastasis
Yes 38 16 (42.1) 22 (57.9)
No 14 4 (28.6) 10 (71.4) 0.288
Proliferation index(Ki-67)
High 39 17 (43.6) 22 (56.4)
Low 13 3 (23.1) 10 (76.9) 0.162
Stage
Early stage 10 3 (30) 7 (70)
Late stage 42 17 (40.5) 25 (59.5) 0.408
Table 2 Receptor status, subtypes and clinical
pathological features
Cancer subtype
Lumina A Lumina B HER2
enriched
TN p-value
Variable n (%) n (%) n (%) n (%)
Age below
50 years
11(61.1) 6(66.6) 1(20) 9(45) 0.282
Lymph node
involvement
11 (61.1) 7(77.7) 4(80) 16(80) 0.568
Ki-67 high
labelling
17(80.9) 4(44.4) 1(50) 17(85) 0.128
Tumour size
above 6 cm
6(33.3) 7 (77.7) 5(100) 13(65) 0.009*
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The mean age at diagnosis of breast cancer was 49 years
old. Four patients (7.7%) were below 30 years of age,
whereas 10 (19.2%) were above 60 years. Fourteen
patients (26.9%) were between 41 and 50 years of age,
followed by 12 (23.1%) who were between 51 and
60 years and 25 (48.1%) above 50 years of age. Tumor
size ranged from 2 cm to 12 cm in diameter with a mean
tumor size of 5.9 cm, with half of the patients (50%)
presenting a tumor size of more than 6 cm. Histological
findings showed that the majority of the tumors were in-
vasive ductal carcinoma 47 (90.4%), followed by invasive
lobular carcinoma 3 (5.8%). One medullary carcinoma
and one micropapillary carcinoma were diagnosed. The
majority of the tumors 40 (76.9%) were of histological
grade III. Thirty eight patients (73.1%) had lymph node
metastasis and 36 (69.2%) were in clinical stage III,
specifically IIIB. Only 3 patients (5.8%) were in clinical
stage I. There was no patient with in situ carcinoma.
There was a tendency for a low level of expression of the
receptors, whereby ER positive tumors were 17 (32.7%),
PR positive tumors were 22 (42.3%) and HER-2 positive
tumors were 12 (23.1%). The proliferation index by KI-67
was high in 39 (75%) of the tumors. Based on the
immuno-histochemical expression of the three markers,
the proportion of breast cancer subtypes seen in this study
were: Lumina A tumors 18 (34.6%), Lumina B tumors 9
(17.3%), HER-2 Enriched tumors 5 (9.6%) and Triple
negative tumors 20 (38.4%). The majority of the patients
were in a late clinical stage at the time of diagnosis and
there was no difference between triple negative and non-
triple negative patients. Triple negative tumors were seen
more frequently in an age above 46 years with no signifi-
cant difference compared to non-triple negative cancers.
However, a small tumor size was more common in triple
negative tumors compared to non-triple negative tumors
with no significant difference and none of the TN tumors
were in histology grade I. There was no difference in lymph
node metastasis and proliferation index between triple
negative and non-triple negative tumors (See Table 1).
The majority of Lumina B tumors were large tumors
of 6 cm and more, followed by triple negative tumors.
Triple negative tumors showed a high proliferation com-
pared to other subtypes with no significant difference.
Lymph node involvement was more common in Triple
Negative and HER-2 enriched tumors. Among patients
below 50 years of age, 11 (61.1%) had lumina A subtype,
followed by Lumina B 6 (66.6%) and triple negative was
9 (45%), (See table 2).
Discussion
The demographic and clinical pathological features seen
in this study were the same as described in two previous
studies, whereas breast cancer was commonly seen inpre-menopausal women at an advanced stage with a
high rate of lymph node metastasis and a large tumour
size [19,20]. This study shows a tendency of a low ex-
pression of ER, PR and HER-2 in the selected patients;
the same trend was observed in Dar-es-Salaam, although
HER-2 was not tested [8], and in the neighbouring
country of Kenya [9]. This shows therefore that only few
patients in these settings would benefit from hormonal
adjuvant therapy. A previous study, undertaken at the
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ment were mainly mastectomy with all the patients hav-
ing been administered post-operative hormonal adjuvant
therapy (tamoxifen). Adjuvant chemotherapy and radio-
therapy was given in 44.8% and 11.7% of patients [20].
Since all the patients were given adjuvant hormonal
therapy without testing the receptors, only 32% (ER+)
benefited from this type of treatment. This shows that
the majority of the patients were unnecessarily exposed
to hormonal therapy which may be associated with side
effects such as ischemic heart diseases, venous throm-
bosis, pulmonary embolism and endometrial cancer [21].
Studies have shown that there is no effect on breast can-
cer outcome on women with ER negative receptors
when exposed to tamoxifen, whereas using of tamoxifen
for more than 10 years in ER positive women with breast
cancer leads to reduced recurrence and mortality [22].
In the current study, 23.1% of the patients were HER-2
positive, comprising the patients who fall under lumina B
and HER-2 enriched tumours, so forming a subgroup of
patients who can benefit from Trastuzumab. These find-
ings did not differ from other studies which showed amp-
lification of this oncogene to be in the range of 14-25%
[4,6]. Patients with lumina B types can benefit from both
hormonal therapy and trastuzumab, while patients with
enriched HER-2 will benefit from trastuzumab only, as
they are negative for hormone receptors. Lumina A tu-
mors were found in 34.6% of the patients who could only
benefit from hormonal therapy as they are negative for
HER-2. Studies have shown that patients with positive ER
had a much better response with trastuzumab than ER
negative patients [23]; this includes patients with lumina B
which comprised only 17.3% of our patients. Other studies
demonstrated that the use of trastuzumab was associated
with a longer time to occurrence of brain metastasis; even
after brain metastasis, the use of this therapy showed a
survival benefit [24].
Triple Negative breast cancers do not express any of
the markers (ER, PR and HER-2). In the present study,
38.4% of the breast cancers fall into this category. These
cancers were commonly seen in high grade tumours
with a high rate of lymph node metastasis, large tumours
size and tumours with necrosis. This type of breast
cancers does not benefit from any of the neo-adjuvant
targeted therapy. In general, TN tumours account for
10-17% of all breast cancers [5,13] and have been ob-
served predominantly in patients of African ethnicity.
This leads to the hypothesis that breast cancer is more
aggressive in those patients. In studies undertaken in
Western countries, breast cancer has proven to be
more aggressive in Native Africans patients [15,25]. TN
tumours tend to occur at a relatively young age with a
more aggressive behaviour in African patients com-
pared to Caucasians, presenting as large tumours, witha high proliferation rate and a high mortality [26]. The
current study shows the same trend, whereby Ki-67
(proliferation marker) labelling was high in TN tumours,
and these tumours were large and showed a tendency for
a high rate of lymph node metastasis. Studies in Kenya
found a prevalence of TN to be 44% (27). The modalities
for neo adjuvant systemic therapy for TN tumours are
either chemotherapy or radiotherapy with a high risk of
recurrence, a high rate of brain metastasis and an overall
poor outcome [28].
Furthermore, TN tumours are said to harbour a subtype
of breast cancer called Basal Like breast Cancer (BLC).
In this study, the marker for BLC was not investigated.
The current study is the first study in Tanzania which
addresses the TN tumours. In East African countries,
Uganda and Kenya, BLC was found to range between 28
and 36% [27]. TN and BLC again form a subtype of
cancers which harbour the carriers for BRCA-1 mutation
[29]. Therefore there is high probability of detecting a
number of patients who are carriers for BRCA-1 mutation
in this setting. This is an area which needs further investi-
gation, as molecular features of breast cancer have been
shown to differ in various geographical locations and
could explain the variability in aggressiveness and the
disease outcome.
Conclusion
This study showed a tendency for a low level expression
of hormonal receptors and significant proportion of
Triple Negative breast cancers with a high proliferation
rate. It is recommended therefore to introduce routine
testing for these markers before initiating hormonal
therapy. Moreover, with the availability of Trasuzumub
in Tanzania, some of the patients would be able to benefit
from this targeted therapy.
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